BridgeBio Oncology Therapeutics market cap BBOT
Share price times shares outstanding: what the whole company sells for, since 2024.
- Today, Nov 2, 2026
- $185.2M
- Highest close in our data
- $1.1B
- Dec 2025
BridgeBio Oncology Therapeutics is worth $185.2M at the close on Nov 2, 2026, at $2.31 a share.
That is down 35% over the last year.
Its highest close in our data was $1.1B in Dec 2025.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $185.2M | $185.2M | $1.1B | −81% |
| 2025 | $986.3M | $207.8M | $1.1B | +291% |
| 2024 | $252M | $234.6M | $253.9M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest BridgeBio Oncology Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| BBOTBridgeBio Oncology Therapeutics | $185.2M |
| NATRNatures Sunshine Products | $211.5M |
| CRMDCorMedix | $420.1M |
| LFVNLifevantage | $73.5M |
| ARVNArvinas | $491.7M |
| PBYIPuma Biotechnology | $525.5M |
| SPROSpero Therapeutics | $60.6M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $599.8M |
| ATNMActinium Pharmaceuticals | $45M |
| COLLCollegium Pharmaceutical | $770.9M |
| Peer median | $455.9M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on BridgeBio Oncology Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.